Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP257301
下载链接
链接失效反馈官方服务：
资源简介：
The mutational landscape of advanced hepatocellular carcinoma is not well investigated and biomarkers of response to systemic therapies in these patients are lacking. We performed targeted ultra-deep DNA sequencing (Agilent SureSelect XTHS) of circulating tumor DNA from blood plasma of 85 individuals (77 advanced HCC, 8 controls with liver cirrhosis), incl. sequential samples and tissue and/or buffy coat, if available (total number of samples 110), and correlated mutation profiles with response to systemic treatment in a subset of patients.
创建时间：
2020-10-26
